Finacea (azelaic acid 15%)

Finacea (azelaic acid 15%) is filed as Topical Anti-Rosacea. The sections below restate public label fields stored for this profile.

Class
Topical Anti-Rosacea
Generic name
azelaic acid 15%
Route
TOPICAL
Dosage forms
3 DOSAGE FORMS AND STRENGTHS Each gram of FINACEA (azelaic acid) Foam contains 0.15 g of azelaic acid (15% w/w) in a white to off-white foam. Foam, 15% ( 3 )
Generic available
Yes
Manufacturer
LEO Pharma Inc.

Approved uses

1 INDICATIONS AND USAGE FINACEA Foam, 15% is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. FINACEA Foam is indicated for the topical treatment of inflammatory papules and pustules of mild to moderate rosacea. ( 1 )

How it works

12.1 Mechanism of Action The mechanism(s) by which azelaic acid interferes with the pathogenic events in rosacea are unknown.

Warnings and precautions

For external use only, avoid the eye area. Avoid direct sunlight during use. Discontinue use immediately if irritation occurs. Store in a cool, dry place.

Contraindications

4 CONTRAINDICATIONS None. None. ( 4 )

Common side effects

Are local site pain (6.2%); Pruritus (2.5%); Dryness (0.7%); And erythema (0.7%)

Adverse reactions

6 ADVERSE REACTIONS The most common adverse reactions are burning/stinging/tingling (29%), pruritus (11%), scaling/dry skin/xerosis (8%) and erythema/irritation (4%). ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In two vehicle-controlled and one active-controlled U.S. clinical trials, treatment safety was monitored in 788 subjects who used twice-daily azelaic acid gel for 12 weeks (N=333) or 15 weeks (N=124), or the gel vehicle (N=331) for 12 weeks. In all three trials, the most common treatment-related adverse events were: burning/stinging/tingling (29%), pruritus (11%), scaling/dry skin/xerosis (8%) and erythema/irritation (4%). In the active-controlled trial, overall adverse reactions (including burning, stinging/tingling, dryness/tightness/scaling, itching, and erythema/irritation/redness) were 19.4% (24/124) for azelaic acid gel compared to 7.1% (9/127) for the active comparator gel at 15 weeks. Table 1: Adverse Events Occurring in ≥1% of Subjects in the Rosacea Trials by Treatment Group and Maximum Intensity * Azelaic acid gel, 15% N=457 (100%) Vehicle N=331 (100%) Mild N=99 (22%) Moderate N=61 (13%) Severe N=27 (6%) Mild N=46 (14%) Moderate N=30 (9%) Severe N=5 (2%) Burning/stinging/tingling 71 (16%) 42 (9%) 17 (4%) 8 (2%) 6 (2%) 2 (1%) Pruritus 29 (6%) 18 (4%) 5 (1%) 9 (3%) 6 (2%) 0 (0%) Scaling/dry skin/ xerosis 21 (5%) 10 (2%) 5 (1%) 31 (9%) 14 (4%) 1 (<1%) Erythema/ irritation 6 (1%) 7 (2%) 2 (<1%) 8 (2%) 4 (1%) 2 (1%) Contact dermatitis 2 (<1%) 3 (1%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) Edema 3 (1%) 2 (<1%) 0 (0%) 3 (1%) 0 (0%) 0 (0%) Acne 3 (1%) 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) * Subjects may have >1 cutaneous adverse event; thus, the sum of the frequencies of preferred terms may exceed the number of subjects with at least 1 cutaneous adverse event. In patients using azelaic acid formulations, the following adverse events have been reported: worsening of asthma, vitiligo, depigmentation, small depigmented spots, hypertrichosis, reddening (signs of keratosis pilaris) and exacerbation of recurrent herpes labialis. Local Tolerability Studies Azelaic acid gel and its vehicle caused irritant reactions at the application site in human dermal safety studies. Azelaic acid gel caused significantly more irritation than its vehicle in a cumulative irritation study. Some improvement in irritation was demonstrated over the course of the clinical trials, but this improvement might be attributed to subject dropouts. No phototoxicity or photoallergenicity were reported in human dermal safety studies. 6.2 Postmarketing Experience The following adverse reactions have been identified post approval of azelaic acid gel. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure: Eyes: iridocyclitis upon accidental exposure of the eyes to azelaic acid gel. Hypersensitivity: angioedema, eye swelling, facial swelling, urticaria. Respiratory: worsening of asthma, dyspnea, wheezing. Skin reactions: application site rash.

Dosage and administration

2 DOSAGE AND ADMINISTRATION Shake well before use. Cleanse affected area(s) using only very mild soaps or soapless cleansing lotion and pat dry with a soft towel before application of FINACEA Foam. Apply FINACEA Foam twice daily (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose). For a single application, dispense the smallest amount of foam necessary to adequately cover the affected area(s) with a thin layer. Use FINACEA Foam continuously over 12 weeks. Wash hands immediately following application of FINACEA Foam. Cosmetics may be applied after the application of FINACEA Foam has dried. Reassess the diagnosis if no improvement is observed upon completing 12 weeks of therapy. Avoid the use of occlusive dressings or wrappings. Instruct patients to avoid use of alcoholic cleansers, tinctures and astringents, abrasives and peeling agents. For topical use. Not for oral, ophthalmic or intravaginal use. Apply a thin layer twice daily (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose). ( 2 ) Use only very mild soaps or soapless cleansing lotion and pat dry with a soft towel before applying FINACEA Foam. ( 2 ) Wash hands immediately following application. ( 2 ) Cosmetics may be applied after the application of FINACEA Foam has dried. ( 2 ) Avoid use of alcoholic cleansers, tinctures and astringents, abrasives and peeling agents. ( 2 ) For topical use. ( 2 ) Not for oral, ophthalmic or intravaginal use. ( 2 )

Common questions

What is Finacea approved to treat?

According to its FDA label, Finacea (azelaic acid 15%) is approved for: 1 INDICATIONS AND USAGE FINACEA Foam, 15% is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. FINACEA Foam is indicated for the topical treatment of inflammatory papules and pustules of mild to moderate rosacea. ( 1 ) For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Finacea?

Finacea (azelaic acid 15%) belongs to the Topical Anti-Rosacea class of medications.

What form does Finacea come in?

The FDA label lists Finacea (azelaic acid 15%) as: 3 DOSAGE FORMS AND STRENGTHS Each gram of FINACEA (azelaic acid) Foam contains 0.15 g of azelaic acid (15% w/w) in a white to off-white foam. Foam, 15% ( 3 ); topical route. Available strengths and packaging vary by manufacturer.

Is there a generic version of Finacea?

Yes. A generic version of Finacea (azelaic acid 15%) is available in the U.S. Ask your pharmacist about substitution.

Does Finacea have a Boxed Warning?

Our ingest of the FDA label for Finacea (azelaic acid 15%) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.

How much does Finacea cost?

Public CMS NADAC pricing for Finacea (azelaic acid 15%) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.

Is Finacea currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Finacea (azelaic acid 15%) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Finacea approved by the FDA?

The FDA record lists the approval date for Finacea (azelaic acid 15%) as 2015-07-29.

Who makes Finacea?

The FDA label lists LEO Pharma Inc. as a labeler/manufacturer of Finacea (azelaic acid 15%). Multiple firms may market generics of the same molecule.

How should Finacea be stored?

The FDA label states: "Storage and Handling Store at 25 ◦ C (77 ◦ F); excursions permitted between 15–30 ◦ C (59–86 ◦ F) [See USP Controlled Room Temperature]. Flammable. Avoid fire, flame, or smoking during and immediately following applicati…" Follow the packaging insert for the authoritative guidance.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…